Breaking News Instant updates and real-time market news.

RDUS

Radius Health

$13.31 /

-0.04 (-0.30%)

08:46
10/21/20
10/21
08:46
10/21/20
08:46

Radius Health provides general business update on progress since May

Radius Health provided a general business update on progress made since May 2020. The Company will provide further updates during its third quarter earnings call and at subsequent investor conferences. The key areas of activity included as part of its update are outlined below. Clinical and Regulatory: Patient enrollment completed for 3 Pivotal Phase III trials: ATOM study evaluating abaloparatide injection for potential use in osteoporotic men with high risk of fracture; wearABLe study evaluating the effects on bone mineral density of abaloparatide delivered via a novel transdermal system; EMERALD study for use of elacestrant to treat ER+/HER2- advanced or metastatic breast cancer in men and postmenopausal women. Japan: Pivotal Phase III trial of abaloparatide injection to treat both men and postmenopausal women; Execution success by Radius partner, Teijin Pharma; Achieved primary endpoint: for osteoporotic patients with high risk for fractures; NDA submitted. Europe: Seeking guidance and clarity regarding possible regulatory re-submission; Histomorphometry Phase 2 Study data: Presented at American Society for Bone and Mineral Research in September; Study assessed the early effect of abaloparatide at the tissue level and demonstrated significant increases in bone formation after three months in postmenopausal women with osteoporosis. Business Development: Completed transaction with Menarini Group for Elacestrant, an oral SERD: Menarini licenses global development and commercial rights; Received $30 million as an upfront payment and up to $320 million in additional milestones along with tiered low to mid-teen royalties; Phase 3 development costs to be fully reimbursed by Menarini Group. Completed transaction with Ellipses Pharma for RAD 140, an oral SARM; Ellipses responsible for all clinical development and advancement; Receive low double-digit percentage of future economics received by Ellipses. US TYMLOS Commercial Business: Re-engineering internal operations: Combined market access with sales and marketing under one umbrella; Reduced sales territories from 159 to 109 and sales regions from 19 to 13; Adjusted incentive compensation plan to incentivize growth in PMO patients at high risk for fracture; Performance Measurement; Net new patients on TYMLOS per month vs. 3 month trailing moving average; Total patients and duration of patients on TYMLOS vs. 3 month moving average; No longer focused on anabolic market share as Radius/TYMLOS business driver. Transparency of TYMLOS performance metrics for the marketplace; Communicate Radius net new patients each month, commencing November 2020; Communicate total Radius patients quarterly, starting with Q1, 2021 results; Share avg. Radius patient months on therapy quarterly, starting Q2, 2021 results. Increasing Current Operating Leverage: Real estate goal: reduce from ~ 60,000 to ~ 12,000 sq. ft. actioning a hybrid work model; Reduced silos at the senior level: consolidated commercial; integrated human resources, information technology, compliance, legal, QA, supply chain and real estate; Total FTE headcount reduced from ~ 400 in 2019 to 315 as of Oct. 1, 2020, an absolute reduction of more than 20 %; Capital allocation: adjusting abaloparatide planned clinical programs to focus on growth through patient segmentation and utilizing existing data with precision of message; Net new patient numbers for Radius: September and October demonstrating growth from mid-year COVID-19 slow down.

  • 05

    Nov

RDUS Radius Health
$13.31 /

-0.04 (-0.30%)

09/29/20 JPMorgan
Radius Health resumed with a Neutral at JPMorgan
08/11/20 Jefferies
Radius Health price target lowered to $14 from $17 at Jefferies
07/08/20 SVB Leerink
Radius Health downgraded to Market Perform from Outperform at SVB Leerink
05/13/20 Morgan Stanley
Radius Health downgraded to Equal Weight following Q1 report at Morgan Stanley

TODAY'S FREE FLY STORIES

Hot Stocks
Athira Pharma initiates patient dosing for ACT-AD trial of ATH-1017 » 07:32
12/01/20
12/01
07:32
12/01/20
07:32
ATHA

Athira Pharma

$24.89 /

+0.82 (+3.41%)

Athira Pharma announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ATHA Athira Pharma
$24.89 /

+0.82 (+3.41%)

ATHA Athira Pharma
$24.89 /

+0.82 (+3.41%)

10/13/20 Jefferies
Athira Pharma initiated with a Buy at Jefferies
10/13/20 JMP Securities
Athira Pharma initiated with an Outperform at JMP Securities
10/13/20 Stifel
Athira Pharma initiated with a Buy at Stifel
10/13/20 Goldman Sachs
Athira Pharma initiated with a Buy at Goldman Sachs
ATHA Athira Pharma
$24.89 /

+0.82 (+3.41%)

  • 18
    Sep
Recommendations
Zoom Video price target raised to $340 from $315 at Credit Suisse » 07:32
12/01/20
12/01
07:32
12/01/20
07:32
ZM

Zoom Video

$479.28 /

+7.98 (+1.69%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ZM Zoom Video
$479.28 /

+7.98 (+1.69%)

ZM Zoom Video
$479.28 /

+7.98 (+1.69%)

07:12 Today William Blair
Zoom Video revenue lower than buy-side expectations, says William Blair
07:06 Today Stifel
Zoom Video price target raised to $450 from $400 at Stifel
07:05 Today Goldman Sachs
Zoom Video price target raised to $460 from $402 at Goldman Sachs
06:09 Today Piper Sandler
Zoom Video shares lower on high investor expectations, says Piper Sandler
ZM Zoom Video
$479.28 /

+7.98 (+1.69%)

ZM Zoom Video
$479.28 /

+7.98 (+1.69%)

ZM Zoom Video
$479.28 /

+7.98 (+1.69%)

ZM Zoom Video
$479.28 /

+7.98 (+1.69%)

Hot Stocks
APi Group announces up to $100M share repurchase program » 07:31
12/01/20
12/01
07:31
12/01/20
07:31
APG

APi Group

$15.50 /

-0.2 (-1.27%)

APi Group announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
APG APi Group
$15.50 /

-0.2 (-1.27%)

APG APi Group
$15.50 /

-0.2 (-1.27%)

09/22/20 Barclays
APi Group initiated with an Overweight at Barclays
08/17/20 UBS
APi Group price target raised to $20 from $15 at UBS
06/24/20 Baird
APi Group initiated with an Outperform at Baird
06/23/20 Baird
APi Group initiated with an Outperform at Baird
APG APi Group
$15.50 /

-0.2 (-1.27%)

Hot Stocks
Moleculin Biotech: FDA approves Rare Pediatric Disease designations for WP1066 » 07:31
12/01/20
12/01
07:31
12/01/20
07:31
MBRX

Moleculin Biotech

$0.78 /

+0.0018 (+0.23%)

Moleculin Biotech…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MBRX Moleculin Biotech
$0.78 /

+0.0018 (+0.23%)

MBRX Moleculin Biotech
$0.78 /

+0.0018 (+0.23%)

04/08/20 Roth Capital
Moleculin can expedite COVID candidate amid less restrictions, says Roth Capital
MBRX Moleculin Biotech
$0.78 /

+0.0018 (+0.23%)

Hot Stocks
Aeglea receives FDA Rare Pediatric Disease Designation for ACN00177 » 07:31
12/01/20
12/01
07:31
12/01/20
07:31
AGLE

Aeglea BioTherapeutics

$8.53 /

-0.12 (-1.39%)

Aeglea BioTherapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AGLE Aeglea BioTherapeutics
$8.53 /

-0.12 (-1.39%)

AGLE Aeglea BioTherapeutics
$8.53 /

-0.12 (-1.39%)

08/10/20 Piper Sandler
Piper Sandler backs Overweight rating on Aeglea BioTherapeutics after Q2 results
05/04/20
Fly Intel: Top five analyst initiations
05/04/20 Piper Sandler
Aeglea BioTherapeutics initiated with an Overweight at Piper Sandler
04/30/20 H.C. Wainwright
Aeglea BioTherapeutics price target lowered to $18 from $24 at H.C. Wainwright
AGLE Aeglea BioTherapeutics
$8.53 /

-0.12 (-1.39%)

  • 28
    Apr
Recommendations
Voya Financial price target raised to $78 from $66 at Credit Suisse » 07:31
12/01/20
12/01
07:31
12/01/20
07:31
VOYA

Voya Financial

$57.65 /

-1.57 (-2.65%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VOYA Voya Financial
$57.65 /

-1.57 (-2.65%)

VOYA Voya Financial
$57.65 /

-1.57 (-2.65%)

11/19/20 Piper Sandler
Voya Financial price target raised to $65 from $57 at Piper Sandler
10/23/20 Piper Sandler
Colorado commissioner hearing a 'distinct positive' for Voya, says Piper Sandler
10/12/20 Gordon Haskett
Voya Financial CEO 'fits the profile of a seller,' says Gordon Haskett
10/01/20 BofA
Voya Financial reinstated with a Buy at BofA
VOYA Voya Financial
$57.65 /

-1.57 (-2.65%)

Recommendations
Texas Roadhouse butcher shop launch looks like 'smart move,' says Stephens » 07:31
12/01/20
12/01
07:31
12/01/20
07:31
TXRH

Texas Roadhouse

$75.75 /

+0.4801 (+0.64%)

Stephens analyst James…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TXRH Texas Roadhouse
$75.75 /

+0.4801 (+0.64%)

TXRH Texas Roadhouse
$75.75 /

+0.4801 (+0.64%)

11/23/20 Baird
Texas Roadhouse upgraded to Outperform from Neutral at Baird
11/23/20 Baird
Texas Roadhouse upgraded to Outperform from Neutral at Baird
11/13/20 Wedbush
Texas Roadhouse price target raised to $90 from $82 at Wedbush
11/02/20 Deutsche Bank
Texas Roadhouse price target raised to $68 from $58 at Deutsche Bank
TXRH Texas Roadhouse
$75.75 /

+0.4801 (+0.64%)

TXRH Texas Roadhouse
$75.75 /

+0.4801 (+0.64%)

Hot Stocks
Eve & Co launches cannabis-infused bath bombs in Ontario » 07:30
12/01/20
12/01
07:30
12/01/20
07:30
EEVVF

Eve & Co

$0.00 /

+ (+0.00%)

Eve & Co Incorporated…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EEVVF Eve & Co
$0.00 /

+ (+0.00%)

Options
Unusual put flow in option market yesterday » 07:30
12/01/20
12/01
07:30
12/01/20
07:30
KSS

Kohl's

$32.19 /

-1.41 (-4.20%)

, CMCSA

Comcast

$50.24 /

-1.52 (-2.94%)

Notable put activity was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KSS Kohl's
$32.19 /

-1.41 (-4.20%)

CMCSA Comcast
$50.24 /

-1.52 (-2.94%)

KSS Kohl's
$32.19 /

-1.41 (-4.20%)

11/19/20 Morgan Stanley
Kohl's price target raised to $27 from $15 at Morgan Stanley
11/18/20 Credit Suisse
Kohl's price target raised to $30 from $23 at Credit Suisse
11/18/20 Deutsche Bank
Kohl's price target raised to $28 from $19 at Deutsche Bank
11/18/20 Citi
Kohl's price target raised to $33 from $21 at Citi
CMCSA Comcast
$50.24 /

-1.52 (-2.94%)

11/25/20 TD Securities
Comcast downgraded to Hold after recent rally at TD Securities
11/25/20 TD Securities
TD Securities downgrades Altice USA to Hold, raises price target to $40
11/25/20 TD Securities
Comcast downgraded to Hold from Buy at TD Securities
11/23/20 Stifel
Dycom price target raised to $90 from $69 at Stifel
KSS Kohl's
$32.19 /

-1.41 (-4.20%)

CMCSA Comcast
$50.24 /

-1.52 (-2.94%)

KSS Kohl's
$32.19 /

-1.41 (-4.20%)

CMCSA Comcast
$50.24 /

-1.52 (-2.94%)

KSS Kohl's
$32.19 /

-1.41 (-4.20%)

CMCSA Comcast
$50.24 /

-1.52 (-2.94%)

KSS Kohl's
$32.19 /

-1.41 (-4.20%)

CMCSA Comcast
$50.24 /

-1.52 (-2.94%)

Downgrade
IHS Markit downgraded to Hold from Buy at Truist » 07:28
12/01/20
12/01
07:28
12/01/20
07:28
INFO

IHS Markit

$99.37 /

+6.85 (+7.40%)

, SPGI

S&P Global

$351.89 /

+10.84 (+3.18%)

Truist analyst Andrew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
INFO IHS Markit
$99.37 /

+6.85 (+7.40%)

SPGI S&P Global
$351.89 /

+10.84 (+3.18%)

INFO IHS Markit
$99.37 /

+6.85 (+7.40%)

06:43 Today Truist
IHS Markit downgraded to Hold from Buy at Truist
06:36 Today RBC Capital
IHS Markit downgraded to Sector Perform from Outperform at RBC Capital
11/30/20 Oppenheimer
S&P Global, IHS Markit would benefit shareholders, says Oppenheimer
09/30/20 Truist
IHS Markit price target raised to $90 from $87 at Truist
SPGI S&P Global
$351.89 /

+10.84 (+3.18%)

06:36 Today RBC Capital
IHS Markit downgraded to Sector Perform from Outperform at RBC Capital
11/30/20
Fly Intel: Top five analyst initiations
11/30/20 Oppenheimer
S&P Global, IHS Markit would benefit shareholders, says Oppenheimer
11/30/20 Deutsche Bank
S&P Global initiated with a Buy at Deutsche Bank
INFO IHS Markit
$99.37 /

+6.85 (+7.40%)

SPGI S&P Global
$351.89 /

+10.84 (+3.18%)

INFO IHS Markit
$99.37 /

+6.85 (+7.40%)

SPGI S&P Global
$351.89 /

+10.84 (+3.18%)

INFO IHS Markit
$99.37 /

+6.85 (+7.40%)

SPGI S&P Global
$351.89 /

+10.84 (+3.18%)

SPGI S&P Global
$351.89 /

+10.84 (+3.18%)

Hot Stocks
Goodfood Market announces C$46M syndicated bank financing » 07:28
12/01/20
12/01
07:28
12/01/20
07:28
GDDFF

Goodfood Market

$0.00 /

+ (+0.00%)

Goodfood Market announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GDDFF Goodfood Market
$0.00 /

+ (+0.00%)

GDDFF Goodfood Market
$0.00 /

+ (+0.00%)

11/12/20 Raymond James
Goodfood Market price target raised to C$12.50 from C$9.15 at Raymond James
11/12/20 Stifel
Goodfood Market price target raised to C$14 from C$12 at Stifel
11/12/20 National Bank
Goodfood Market price target raised to C$11 from C$10.50 at National Bank
11/09/20 Stifel
Goodfood Market price target raised to C$12 from C$10 at Stifel
Upgrade
Credit Suisse upgrades Lincoln National to Outperform with $56 target » 07:28
12/01/20
12/01
07:28
12/01/20
07:28
LNC

Lincoln National

$47.23 /

-1.92 (-3.91%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LNC Lincoln National
$47.23 /

-1.92 (-3.91%)

LNC Lincoln National
$47.23 /

-1.92 (-3.91%)

07:09 Today Credit Suisse
Lincoln National upgraded to Outperform from Neutral at Credit Suisse
11/17/20 Barclays
Lincoln National initiated with an Equal Weight at Barclays
10/23/20 Citi
Citi opens '30-day positive catalyst watch' on Lincoln National
07/16/20 Credit Suisse
Lincoln National price target lowered to $41 from $52 at Credit Suisse
LNC Lincoln National
$47.23 /

-1.92 (-3.91%)

LNC Lincoln National
$47.23 /

-1.92 (-3.91%)

Hot Stocks
CareDx announces publication on AlloSure in pediatric patients » 07:26
12/01/20
12/01
07:26
12/01/20
07:26
CDNA

CareDx

$31.00 /

+17 (+7.00%)

CareDx announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CDNA CareDx
$31.00 /

+17 (+7.00%)

CDNA CareDx
$31.00 /

+17 (+7.00%)

11/17/20 Piper Sandler
CareDx reimbursement well above expectations, says Piper Sandler
10/30/20 Raymond James
CareDx price target raised to $62 from $42 at Raymond James
10/30/20 H.C. Wainwright
CareDx price target raised to $55 from $47 at H.C. Wainwright
10/08/20 BTIG
CareDx price target raised to $55 from $45 at BTIG
CDNA CareDx
$31.00 /

+17 (+7.00%)

  • 11
    Jun
CDNA CareDx
$31.00 /

+17 (+7.00%)

Recommendations
Adient price target raised to $36 from $29 at Credit Suisse » 07:26
12/01/20
12/01
07:26
12/01/20
07:26
ADNT

Adient

$31.20 /

-2.76 (-8.13%)

Credit Suisse analyst Dan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ADNT Adient
$31.20 /

-2.76 (-8.13%)

ADNT Adient
$31.20 /

-2.76 (-8.13%)

07:19 Today KeyBanc
Adient price target raised to $36 from $31 at KeyBanc
06:43 Today RBC Capital
Adient price target raised to $38 from $24 at RBC Capital
11/17/20 BofA
Adient, Aptiv get double downgrades as BofA reshuffles auto industry ratings
11/17/20 BofA
Adient downgraded to Underperform from Buy at BofA
ADNT Adient
$31.20 /

-2.76 (-8.13%)

Hot Stocks
Semtech, CNIguard, Senet collaborate for natural gas monitoring solutions » 07:25
12/01/20
12/01
07:25
12/01/20
07:25
SMTC

Semtech

$67.42 /

-1.4 (-2.03%)

Senet announced it is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SMTC Semtech
$67.42 /

-1.4 (-2.03%)

SMTC Semtech
$67.42 /

-1.4 (-2.03%)

11/30/20 B. Riley Securities
Semtech price target raised to $83 from $72 at B. Riley Securities
11/25/20 Oppenheimer
Semtech price target raised to $75 from $65 at Oppenheimer
08/27/20 B. Riley FBR
Semtech price target raised to $72 from $65 at B. Riley FBR
08/27/20 Wells Fargo
Semtech price target raised to $67 from $57 at Wells Fargo
SMTC Semtech
$67.42 /

-1.4 (-2.03%)

SMTC Semtech
$67.42 /

-1.4 (-2.03%)

Recommendations
Abercrombie & Fitch price target raised to $14 from $10 at Morgan Stanley » 07:24
12/01/20
12/01
07:24
12/01/20
07:24
ANF

Abercrombie & Fitch

$20.75 /

-1.9 (-8.39%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ANF Abercrombie & Fitch
$20.75 /

-1.9 (-8.39%)

ANF Abercrombie & Fitch
$20.75 /

-1.9 (-8.39%)

11/25/20 Baird
Abercrombie & Fitch price target raised to $24 from $14 at Baird
11/25/20 B. Riley Securities
Abercrombie & Fitch price target raised to $27 from $22 at B. Riley Securities
11/25/20 RBC Capital
Abercrombie & Fitch price target raised to $25 from $14 at RBC Capital
11/25/20 Citi
Abercrombie & Fitch price target raised to $28 from $20 at Citi
ANF Abercrombie & Fitch
$20.75 /

-1.9 (-8.39%)

ANF Abercrombie & Fitch
$20.75 /

-1.9 (-8.39%)

Upgrade
Verisk Analytics upgraded to Buy from Hold at Truist » 07:24
12/01/20
12/01
07:24
12/01/20
07:24
VRSK

Verisk Analytics

$198.16 /

+0.12 (+0.06%)

Truist analyst Andrew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VRSK Verisk Analytics
$198.16 /

+0.12 (+0.06%)

VRSK Verisk Analytics
$198.16 /

+0.12 (+0.06%)

06:44 Today Truist
Verisk Analytics upgraded to Buy from Hold at Truist
11/09/20 BMO Capital
Verisk Analytics price target raised to $196 from $181 at BMO Capital
11/06/20 Barclays
Verisk Analytics price target raised to $220 from $210 at Barclays
11/05/20 Deutsche Bank
Verisk Analytics price target raised to $192 from $183 at Deutsche Bank
VRSK Verisk Analytics
$198.16 /

+0.12 (+0.06%)

Hot Stocks
BioCardia announces publication of study using Helix System » 07:23
12/01/20
12/01
07:23
12/01/20
07:23
BCDA

BioCardia

$2.35 /

-0.01 (-0.42%)

BioCardia announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BCDA BioCardia
$2.35 /

-0.01 (-0.42%)

BCDA BioCardia
$2.35 /

-0.01 (-0.42%)

09/21/20
Fly Intel: Top five analyst initiations
09/21/20 Alliance Global Partners
BioCardia initiated with a Buy at Alliance Global Partners
BCDA BioCardia
$2.35 /

-0.01 (-0.42%)

Hot Stocks
Adicet Bio appoints Bastiano Sanna to board of directors » 07:22
12/01/20
12/01
07:22
12/01/20
07:22
ACET

Adicet Bio

$12.33 /

-0.26 (-2.07%)

, VRTX

Vertex Pharmaceuticals

$227.94 /

+1.39 (+0.61%)

Adicet Bio (ACET)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ACET Adicet Bio
$12.33 /

-0.26 (-2.07%)

VRTX Vertex Pharmaceuticals
$227.94 /

+1.39 (+0.61%)

ACET Adicet Bio
$12.33 /

-0.26 (-2.07%)

11/04/20
Fly Intel: Top five analyst initiations
11/04/20 B. Riley Securities
B. Riley sees 200% potential upside in 'attractive value play' Adicet Bio
11/04/20 B. Riley Securities
Adicet Bio initiated with a Buy at B. Riley Securities
10/27/20 JMP Securities
Adicet Bio initiated with an Outperform at JMP Securities
VRTX Vertex Pharmaceuticals
$227.94 /

+1.39 (+0.61%)

11/30/20 RBC Capital
Vertex Pharmaceuticals upgraded to Outperform from Sector Perform at RBC Capital
11/30/20 RBC Capital
Vertex upgraded to Outperform from Sector Perform at RBC Capital
11/20/20
Fly Intel: Top five analyst initiations
11/20/20 Bernstein
Vertex Pharmaceuticals initiated with an Outperform at Bernstein
VRTX Vertex Pharmaceuticals
$227.94 /

+1.39 (+0.61%)

  • 24
    Sep
VRTX Vertex Pharmaceuticals
$227.94 /

+1.39 (+0.61%)

VRTX Vertex Pharmaceuticals
$227.94 /

+1.39 (+0.61%)

ACET Adicet Bio
$12.33 /

-0.26 (-2.07%)

VRTX Vertex Pharmaceuticals
$227.94 /

+1.39 (+0.61%)

Hot Stocks
IBI Group announces asset acquisition of Cole Engineering Group » 07:20
12/01/20
12/01
07:20
12/01/20
07:20
IBIBF

IBI Group

$0.00 /

+ (+0.00%)

IBI Group announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
IBIBF IBI Group
$0.00 /

+ (+0.00%)

11/09/20 Raymond James
IBI Group price target raised to C$9 from C$8 at Raymond James
Recommendations
Discovery price target raised to $28 from $22 at Morgan Stanley » 07:20
12/01/20
12/01
07:20
12/01/20
07:20
DISCK

Discovery Inc.

$24.02 /

-0.53 (-2.16%)

, DISCA

Discovery

$26.91 /

-0.59 (-2.15%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DISCK Discovery Inc.
$24.02 /

-0.53 (-2.16%)

DISCA Discovery
$26.91 /

-0.59 (-2.15%)

DISCK Discovery Inc.
$24.02 /

-0.53 (-2.16%)

DISCA Discovery
$26.91 /

-0.59 (-2.15%)

09/23/20
Fly Intel: Top five analyst downgrades
09/23/20 JPMorgan
Discovery downgraded to Neutral on DTC challenges at JPMorgan
09/23/20 JPMorgan
Discovery downgraded to Neutral from Overweight at JPMorgan
08/19/20 MKM Partners
Discovery price target raised to $27 from $26 at MKM Partners
DISCA Discovery
$26.91 /

-0.59 (-2.15%)

DISCA Discovery
$26.91 /

-0.59 (-2.15%)

DISCA Discovery
$26.91 /

-0.59 (-2.15%)

DISCA Discovery
$26.91 /

-0.59 (-2.15%)

Upgrade
Pinterest upgraded to Buy from Hold at Argus » 07:20
12/01/20
12/01
07:20
12/01/20
07:20
PINS

Pinterest

$70.02 /

+0.59 (+0.85%)

Argus analyst Jim…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PINS Pinterest
$70.02 /

+0.59 (+0.85%)

PINS Pinterest
$70.02 /

+0.59 (+0.85%)

11/19/20 Loop Capital
Pinterest price target raised to $80 from $44 at Loop Capital
11/02/20 Rosenblatt
Pinterest price target raised to $55 from $40 at Rosenblatt
10/30/20 Citi
Pinterest price target raised to $65 from $35 at Citi
10/29/20 Wedbush
Pinterest price target raised to $74 from $58.74 at Wedbush
PINS Pinterest
$70.02 /

+0.59 (+0.85%)

PINS Pinterest
$70.02 /

+0.59 (+0.85%)

PINS Pinterest
$70.02 /

+0.59 (+0.85%)

PINS Pinterest
$70.02 /

+0.59 (+0.85%)

Hot Stocks
Intrusion appoints Franklin Byrd as CFO » 07:19
12/01/20
12/01
07:19
12/01/20
07:19
INTZ

Intrusion

$11.81 /

-1.71 (-12.65%)

INTRUSION has appointed…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
INTZ Intrusion
$11.81 /

-1.71 (-12.65%)

INTZ Intrusion
$11.81 /

-1.71 (-12.65%)

10/15/20 B. Riley Securities
B. Riley sees 'transformational growth' for Intrusion, starts with Buy rating
10/14/20 B. Riley Securities
Intrusion initiated with a Buy at B. Riley Securities
  • 09
    Oct
Recommendations
Adient price target raised to $36 from $31 at KeyBanc » 07:19
12/01/20
12/01
07:19
12/01/20
07:19
ADNT

Adient

$31.20 /

-2.76 (-8.13%)

KeyBanc analyst James…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ADNT Adient
$31.20 /

-2.76 (-8.13%)

ADNT Adient
$31.20 /

-2.76 (-8.13%)

06:43 Today RBC Capital
Adient price target raised to $38 from $24 at RBC Capital
11/17/20 BofA
Adient, Aptiv get double downgrades as BofA reshuffles auto industry ratings
11/17/20 BofA
Adient downgraded to Underperform from Buy at BofA
10/22/20 JPMorgan
Adient price target raised to $17 from $13 at JPMorgan
ADNT Adient
$31.20 /

-2.76 (-8.13%)

Hot Stocks
Nasdaq files proposal to adopt new listing rules related to board diversity » 07:18
12/01/20
12/01
07:18
12/01/20
07:18
NDAQ

Nasdaq

$128.04 /

+1.06 (+0.83%)

Nasdaq filed a proposal…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NDAQ Nasdaq
$128.04 /

+1.06 (+0.83%)

NDAQ Nasdaq
$128.04 /

+1.06 (+0.83%)

11/20/20 Keefe Bruyette
Nasdaq upgraded to Outperform from Market Perform at Keefe Bruyette
11/11/20 Deutsche Bank
Nasdaq price target raised to $168 from $152 at Deutsche Bank
10/22/20 Deutsche Bank
Nasdaq price target raised to $152 from $147 at Deutsche Bank
09/11/20 Loop Capital
Loop Capital initiates exchanges, market-structure names w/ fintech focus
NDAQ Nasdaq
$128.04 /

+1.06 (+0.83%)

NDAQ Nasdaq
$128.04 /

+1.06 (+0.83%)

NDAQ Nasdaq
$128.04 /

+1.06 (+0.83%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.